Artal Group’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-33,333
Closed -$10.8M 111
2019
Q4
$10.8M Sell
33,333
-6,667
-17% -$1.93M 0.42% 43
2019
Q3
$10.9M Buy
40,000
+33,333
+500% +$12.2M 0.44% 43
2019
Q2
$3.56M Hold
6,667
0.14% 90
2019
Q1
$3.36M Sell
6,667
-6,666
-50% -$3.95M 0.14% 88
2018
Q4
$6.57M Hold
13,333
0.24% 60
2018
Q3
$12.2M Sell
13,333
-6,667
-33% -$5.69M 0.32% 44
2018
Q2
$14.6M Buy
20,000
+6,667
+50% +$7.69M 0.31% 35
2018
Q1
$21.3M Sell
13,333
-60,000
-82% -$77.3M 0.27% 30
2017
Q4
$65.7M Buy
73,333
+33,333
+83% +$19.7M 0.99% 10
2017
Q3
$14.4M Sell
40,000
-26,667
-40% -$8.34M 0.25% 30
2017
Q2
$19.6M Buy
66,667
+33,334
+100% +$9.63M 0.34% 26
2017
Q1
$11.7M Hold
33,333
0.26% 36
2016
Q4
$6.13M Buy
+33,333
New +$6.78M 0.14% 51
2015
Q2
Sell
-20,000
Closed -$3.3M 85
2015
Q1
$3.3M Buy
+20,000
New +$4.11M 0.15% 65
2014
Q3
Sell
-53,333
Closed -$10.3M 96
2014
Q2
$10.3M Buy
53,333
+33,333
+167% +$5.9M 0.41% 48
2014
Q1
$3.64M Buy
+20,000
New +$3.96M 0.13% 80

Other funds holding NKTR

Artal Group's NKTR Position: Q3 2020 in Review

Artal Group sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 15,933 shares — an estimated $5.54M sold.

Artal Group first reported a position in NKTR in Q2 2013 and held it in 27 quarters. The position peaked at $74.4M in Q1 2018. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Artal Group reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Artal Group sold 15,933 Nektar Therapeutics shares in Q3 2020, an estimated $5.54M.
  • Artal Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 27 quarters.
  • Artal Group's Nektar Therapeutics position peaked at $74.4M in Q1 2018.
  • 249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.